Although constitutional delay of growth and puberty (CDGP) can be considered a normal variant, it remains the most common reason for boys presenting to an endocrine clinic. Many are referred because measurements by school doctors or general practitioners show them to be 'falling through' or 'falling away from' the height centiles or because of parents' concerns. Many boys will not perceive their short stature or lack of sexual development as a significant problem. Others may be distressed by lack of stature, sexual development or both. Pathology may need excluding but psychological stresses are not in any way dependent on its presence.1
In some, explanation may be all that is required. This must be based on knowledge of the natural history of pubertal development and growth, and an empathy with the psychological pressures that being 'different' in adolescence in terms of size and sexual development can bring. In others, emotional and psychological support will be necessary. However, it may be appropriate to attempt to bring forward the timing of the pubertal growth spurt This and a number of other short term studies of androgen, anabolic steroid, or growth hormone treatments have reported outcomes in sometimes diverse groups of patients, without long term follow up (off treatment or to final height), without psychological assessments and leave some important questions unanswered. Carefully controlled long term prospective trials to determine the criteria for considering treatment, the optimum regimen for growth stimulation and pubertal progression, and psychological outcomes in treated and untreated adolescents are necessary, and in progress.
Boys with CDGP, unless against a background of familial short stature, will reach a final height within the normal range. Increased adult height (even if achievable) may not be the most important anthropometric outcome in CDGP. Nevertheless, many may not reach their genetic height potential3 and in this study there was retrospective evidence of significant psychological distress in adolescence and a strong desire, in those questioned, to have received treatment to advance their growth spurt.
There is no substitute for long term follow up. Height prediction is fraught with difficulties particularly at around the time of puberty and is least accurate (and therefore least useful) in individuals showing marked deviations from the mean in terms of height, height velocity, and skeletal maturation. It is dependent on bone age estimation, which has an inherent assessment error that is greater between observers (often the case in multicentre growth trials) than when a single observer blinded to the clinical situation is responsible.
There could be other than psychological consequences of CDGP. The timing of puberty may be an important determinant of adult bone mineral density and those with CDGP could be at greater risk of osteoporosis in later adulthood. 4 The full effects of anabolic steroids on bone maturation5
may not be evident for over six months after treatment is discontinued and skeletal maturation may continue to advance for up to a year. Thus when interpreting the effects of courses of anabolic steroids on growth, and in particular on predicted height, follow up data in the period after treatment are required. This is not reported in all studies (for example, Albanese et al2). Anabolic steroids may have a greater effect on skeletal maturation in younger children than in those whose bone age is approaching that of puberty. This may reflect a difference in sensitivity of the epiphyseal cartilage at an age when it is not normally subjected to androgens, or a greater resistance of more mature epiphyseal cartilage to exogenous influence since it is already under the influence of endogenous gonadal steroids. However, this may be a dose related phenomenon and effects on skeletal maturation (even when studied long term) need to be interpreted with caution and related to age, pubertal stage, dose and time on treatment. Oxandrolone thus seems to be an excellent growth promoter in late prepubertal boys with significant growth and maturational delay,2 6 7 but there have not been ideally controlled studies in homogeneous groups of patients with sufficiently long follow up to be confident about its effects on sexual maturation in late prepuberty (as opposed to early to mid puberty) or on final height. Its effects on sexual maturation may be age and pubertal stage dependent -results obtained in a given age group at a particular pubertal stage cannot automatically be applied to other situations.
When oxandrolone is used, it should be in the minimum practical dose (1 25-2-5 mg orally daily).5 Its availability long term is in doubt (partly because of its potential for, and documented, abuse by body builders and athletes) and is an unlicensed treatment currently available only on a named patient basis. The commonly used injectable form of testosterone in the UK has been a mixture of long acting testosterone esters (Sustanon). There are surprisingly few detailed studies on its use in boys with puberty delay. Even with low dosage, supraphysiological levels of testosterone are unavoidable in the first 48-72 hours after injection, followed by gradual waning of effect over the next 3-4 weeks. In spontaneous pubertal development, more or less constant testosterone concentrations are found physiologically only when puberty is relatively far advanced. This pattern of testosterone exposure, with the depot released over weeks, is therefore very unphysiological compared with early male puberty, where there is a rise in testosterone in the morning (due to increasing nocturnal luteinising hormone pulsatility) followed by a fall during the day.8 9 A role for recombinant human growth hormone treatment in boys with familial short stature and CDGP has been considered and is the subject of other current studies. The potential use of growth hormone in these contexts could usefully be explored further in studies concentrating on short term treatment regimens. There is currently a lack of such studies specifically designed to look at both medium term growth effects and final height in terms of, for example, optimal age for starting, dosage regimens, incremental doses, intermittent courses, 'catch-down' growth, and psychological outcomes. Such studies could provide data that would allow treatment to be optimised and, perhaps, cost effective. 13 Much remains to be done in evaluating scientifically, in growth, pubertal and psychological terms, the most appropriate treatment interventions in different groups of 'short normal' children (with CDGP or familial short stature) at different ages. In such studies, which are in progress, assessing feelings is as important as assessing height, testicular volumes, bone mineral density, or 
